Continuous Erythropoietin Receptor Activator for the Treatment of Chronic Dialysis Patients with Renal Anemia in Daily Clinical Practice in Poland: A Non-Interventional, Multi-Center, Pragmatic NAVIGO Trial
Nephron · 2024
DOI: 10.1159/000534070 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephron, 2024. Verfasst von Michał Nowicki und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Hypertension and Kidney Transplantation, Medical University of Łódź, Łódź, Poland. Hauptthemen laut MEDLINE: Erythropoietin, Anemia, Renal Insufficiency, Chronic, Hematinics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Renal anemia is one of the most common complications of chronic kidney disease (CKD). This real-life study assessed the effectiveness of methoxy polyethylene glycol-epoetin beta, a continuous erythropoietin receptor activator (C.E.R.A.), for the treatment of CKD-associated anemia in patients receiving dialysis in daily clinical practice.
Methods
247 patients receiving chronic intermitted dialysis in 26 centers in Poland with CKD-associated symptomatic anemia, ESA-naïve, and with balanced iron stores in the investigators’ opinion were enrolled this real-life study. Over 12 months, the following data were collected: hemoglobin (Hb) concentration and dosage, route of administration and dosing scheme of C.E.R.A., dialysis adequacy, adverse events, iron therapy, and blood transfusions.
Results
During the treatment, a Hb concentration of ≥10 g/dL was noted in 90.9% of hemodialysis patients (n = 224) and 96.0% of peritoneal dialysis patients (n = 23). At baseline, 7.8% of patients had a Hb concentration of 10–12 g/dL, which increased to 63.3% after 12 months. The median time when Hb concentration was maintained within 10–12 g/dL was 115.2 (interquartile range 49.1–188.7) days. A Hb concentration ≥12 g/dL was observed after 7 months of treatment in a maximum of 24.1% of hemodialysis patients, and 31.8% of peritoneal dialysis patients. The median time elapsed between the start of treatment and the first Hb concentration >10 g/dL was 42.0 (21.0–78.2) days. C.E.R.A. was well tolerated.
Conclusions
C.E.R.A. corrects CKD-associated anemia in dialysis patients, and maintains Hb levels within the recommended target range. The study also confirmed the acceptable safety profile of the drug.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Hypertension and Kidney Transplantation, Medical University of Łódź, Łódź, Poland.
- DaVita Sp. z o.o., Wrocław, Poland.
- Department of Internal Medicine with Nephrology Division, Specialistic Voivodeship Hospital, Rybnik, Poland.
- Department of Nephrology, Specialistic Voivodeship Hospital, Ciechanów, Poland.
- Institute of Education I.E., Warsaw, Poland.
Zitieren
APA
Nowicki, M., Drożdż, M., Wajda, J., Klatko, W., & Segiet-Święcicka, A. (2024). Continuous Erythropoietin Receptor Activator for the Treatment of Chronic Dialysis Patients with Renal Anemia in Daily Clinical Practice in Poland: A Non-Interventional, Multi-Center, Pragmatic NAVIGO Trial. Nephron. https://doi.org/10.1159/000534070
Vancouver
Nowicki M, Drożdż M, Wajda J, Klatko W, Segiet-Święcicka A. Continuous Erythropoietin Receptor Activator for the Treatment of Chronic Dialysis Patients with Renal Anemia in Daily Clinical Practice in Poland: A Non-Interventional, Multi-Center, Pragmatic NAVIGO Trial. Nephron. 2024. doi:10.1159/000534070
BibTeX
@article{Nowicki2024,
author = {Nowicki, Michał and Drożdż, Maciej and Wajda, Jarosław and Klatko, Wiesław and Segiet-Święcicka, Agnieszka},
title = {Continuous Erythropoietin Receptor Activator for the Treatment of Chronic Dialysis Patients with Renal Anemia in Daily Clinical Practice in Poland: A Non-Interventional, Multi-Center, Pragmatic NAVIGO Trial},
journal = {Nephron},
year = {2024},
doi = {10.1159/000534070}
}
EUVIMED